Literature DB >> 19840825

Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity.

Yeu-Chun Kim1, Fu-Shi Quan, Richard W Compans, Sang-Moo Kang, Mark R Prausnitz.   

Abstract

Microneedle patches coated with solid-state influenza vaccine have been developed to improve vaccine efficacy and patient coverage. However, dip coating microneedles with influenza vaccine can reduce antigen activity. In this study, we sought to determine the experimental factors and mechanistic pathways by which inactivated influenza vaccine can lose activity, as well as develop and assess improved microneedle coating formulations that protect the antigen from activity loss. After coating microneedles using a standard vaccine formulation, the stability of influenza vaccine was reduced to just 2%, as measured by hemagglutination activity. The presence of carboxymethylcellulose, which was added to increase viscosity of the coating formulation, was shown to contribute to vaccine activity loss. After screening a panel of candidate stabilizers, the addition of trehalose to the coating formulation was found to protect the antigen and retain 48-82% antigen activity for all three major strains of seasonal influenza: H1N1, H3N2 and B. Influenza vaccine coated in this way also exhibited thermal stability, such that activity loss was independent of temperature over the range of 4-37 degrees C for 24h. Dynamic light scattering measurements showed that antigen activity loss was associated with virus particle aggregation, and that stabilization using trehalose largely blocked this aggregation. Finally, microneedles using an optimized vaccine coating formulation were applied to the skin to vaccinate mice. Microneedle vaccination induced robust systemic and functional antibodies and provided complete protection against lethal challenge infection similar to conventional intramuscular injection. Overall, these results show that antigen activity loss during microneedle coating can be largely prevented through optimized formulation and that stabilized microneedle patches can be used for effective vaccination. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19840825      PMCID: PMC2823933          DOI: 10.1016/j.jconrel.2009.10.013

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  49 in total

1.  Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system.

Authors:  Philippe E Laurent; Stephane Bonnet; Paul Alchas; Paulina Regolini; John A Mikszta; Ronald Pettis; Noel G Harvey
Journal:  Vaccine       Date:  2007-10-29       Impact factor: 3.641

2.  Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults.

Authors:  Pierre Van Damme; Froukje Oosterhuis-Kafeja; Marie Van der Wielen; Yotam Almagor; Ofer Sharon; Yotam Levin
Journal:  Vaccine       Date:  2008-11-18       Impact factor: 3.641

3.  Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial.

Authors:  David Holland; Robert Booy; Ferdinandus De Looze; Peter Eizenberg; James McDonald; Jeff Karrasch; Maureen McKeirnan; Hatem Salem; Graham Mills; Jim Reid; Françoise Weber; Melanie Saville
Journal:  J Infect Dis       Date:  2008-09-01       Impact factor: 5.226

4.  Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults.

Authors:  Isabel Leroux-Roels; Eva Vets; Ralf Freese; Michael Seiberling; Françoise Weber; Camille Salamand; Geert Leroux-Roels
Journal:  Vaccine       Date:  2008-12-02       Impact factor: 3.641

Review 5.  Vaccines against epidemic and pandemic influenza.

Authors:  Mary Hoelscher; Shivaprakash Gangappa; Weimin Zhong; Lakshmi Jayashankar; Suryaprakash Sambhara
Journal:  Expert Opin Drug Deliv       Date:  2008-10       Impact factor: 6.648

6.  Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008.

Authors:  Anthony E Fiore; David K Shay; Karen Broder; John K Iskander; Timothy M Uyeki; Gina Mootrey; Joseph S Bresee; Nancy S Cox
Journal:  MMWR Recomm Rep       Date:  2008-08-08

7.  Induction of heterosubtypic immunity to influenza virus by intranasal immunization.

Authors:  Fu-Shi Quan; Richard W Compans; Huan H Nguyen; Sang-Moo Kang
Journal:  J Virol       Date:  2007-11-21       Impact factor: 5.103

Review 8.  Development of stable influenza vaccine powder formulations: challenges and possibilities.

Authors:  J-P Amorij; A Huckriede; J Wilschut; H W Frijlink; W L J Hinrichs
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

9.  Effect of microneedle design on pain in human volunteers.

Authors:  Harvinder S Gill; Donald D Denson; Brett A Burris; Mark R Prausnitz
Journal:  Clin J Pain       Date:  2008-09       Impact factor: 3.442

10.  Transdermal influenza immunization with vaccine-coated microneedle arrays.

Authors:  Dimitrios G Koutsonanos; Maria del Pilar Martin; Vladimir G Zarnitsyn; Sean P Sullivan; Richard W Compans; Mark R Prausnitz; Ioanna Skountzou
Journal:  PLoS One       Date:  2009-03-10       Impact factor: 3.240

View more
  80 in total

1.  Bacillus Calmette-Guérin vaccination using a microneedle patch.

Authors:  Yasuhiro Hiraishi; Subhadra Nandakumar; Seong-O Choi; Jeong Woo Lee; Yeu-Chun Kim; James E Posey; Suraj B Sable; Mark R Prausnitz
Journal:  Vaccine       Date:  2011-01-28       Impact factor: 3.641

2.  DNA vaccination in the skin using microneedles improves protection against influenza.

Authors:  Jae-Min Song; Yeu-Chun Kim; Eunju O; Richard W Compans; Mark R Prausnitz; Sang-Moo Kang
Journal:  Mol Ther       Date:  2012-04-17       Impact factor: 11.454

3.  In vivo, in situ imaging of microneedle insertion into the skin of human volunteers using optical coherence tomography.

Authors:  Siôn A Coulman; James C Birchall; Aneesh Alex; Marc Pearton; Bernd Hofer; Conor O'Mahony; Wolfgang Drexler; Boris Považay
Journal:  Pharm Res       Date:  2010-05-13       Impact factor: 4.200

Review 4.  Skin permeabilization for transdermal drug delivery: recent advances and future prospects.

Authors:  Carl M Schoellhammer; Daniel Blankschtein; Robert Langer
Journal:  Expert Opin Drug Deliv       Date:  2014-01-07       Impact factor: 6.648

Review 5.  Polymeric microneedles for transdermal protein delivery.

Authors:  Yanqi Ye; Jicheng Yu; Di Wen; Anna R Kahkoska; Zhen Gu
Journal:  Adv Drug Deliv Rev       Date:  2018-01-31       Impact factor: 15.470

6.  Parathyroid hormone PTH(1-34) formulation that enables uniform coating on a novel transdermal microprojection delivery system.

Authors:  Mahmoud Ameri; Shelley C Fan; Yuh-Fun Maa
Journal:  Pharm Res       Date:  2009-12-15       Impact factor: 4.200

7.  Microneedle patch delivery to the skin of virus-like particles containing heterologous M2e extracellular domains of influenza virus induces broad heterosubtypic cross-protection.

Authors:  Min-Chul Kim; Jeong Woo Lee; Hyo-Jick Choi; Yu-Na Lee; Hye Suk Hwang; Jongsang Lee; Cheol Kim; Jong Seok Lee; Carlo Montemagno; Mark R Prausnitz; Sang-Moo Kang
Journal:  J Control Release       Date:  2015-05-21       Impact factor: 9.776

8.  Intradermal delivery of vaccines: potential benefits and current challenges.

Authors:  J K Hickling; K R Jones; M Friede; D Zehrung; D Chen; D Kristensen
Journal:  Bull World Health Organ       Date:  2011-01-05       Impact factor: 9.408

Review 9.  Targeting the skin for microneedle delivery of influenza vaccine.

Authors:  Dimitrios G Koutsonanos; Richard W Compans; Ioanna Skountzou
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

10.  Stability of whole inactivated influenza virus vaccine during coating onto metal microneedles.

Authors:  Hyo-Jick Choi; Brian J Bondy; Dae-Goon Yoo; Richard W Compans; Sang-Moo Kang; Mark R Prausnitz
Journal:  J Control Release       Date:  2012-12-13       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.